Evidence map›Paper›PMID 41852939›Full record

ArticleJTO clinical and research reports2026

Immune Checkpoint Inhibitor Outcomes in NSCLC Across Populations and Practice Settings.

Matthew Lee, Jialing Liu, Kari J Teigen, Krishti Sabloak, Melissa Howell, Mario Gonzalez, Bassam Ghabach, David E Gerber, Kalyani Narra, Mitchell S von Itzstein

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matthew LeeUT Southwestern Medical School, University of Texas Southwestern Medical Center, Dallas, Texas.
Jialing LiuHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Kari J TeigenOffice of Clinical Research, JPS Health Network, Fort Worth, Texas.
Krishti SabloakTexas College of Osteopathic Medicine, Fort Worth, Texas.
Melissa HowellIT Business Intelligence, JPS Health Network, Fort Worth, Texas.
Mario GonzalezJPS Oncology and Infusion Center, Fort Worth, Texas.
Bassam GhabachJPS Oncology and Infusion Center, Fort Worth, Texas.
David E GerberHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Kalyani NarraJPS Oncology and Infusion Center, Fort Worth, Texas.
Mitchell S von ItzsteinHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Immune checkpoint inhibitor (ICI) clinical trials generally enroll non-Hispanic White patients at academic or private practice settings. ICI outcomes at safety-net settings and across diverse populations remain limited. Methods: We conducted a retrospective study of patients with advanced NSCLC treated in a safety-net health care system and at an academic cancer center. We obtained clinical and demographic data from the electronic medical record. Kaplan-Meier estimates and Cox proportional hazards model were used to assess variables associated with survival. Results: A total of 408 patients were included. Compared with the academic center cohort (n = 213), the safety-net cohort (n = 195) was younger (35% versus 75% ≥ 65 y old; Conclusion: In a diverse cohort across practice settings, receipt of ICI was associated with improved survival, regardless of facility type, race and ethnicity, or socioeconomic status. Efforts to provide ICI access to all eligible patients may improve outcomes.

Indexed as

ICINon–small cell lung cancerReal-worldSafety-net

Identifiers

PMID41852939
PMCPMC12992504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.